Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot

Trial Profile

Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2014

At a glance

  • Drugs Dalteparin sodium (Primary) ; Heparin
  • Indications Embolism and thrombosis
  • Focus Pharmacodynamics
  • Acronyms HALO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Jul 2013 Planned end date changed from 1 Sep 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
    • 31 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top